Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to -$956.0 million.

  • United Therapeutics' Cash from Financing Activities fell 139141.97% to -$956.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 394.38%. This contributed to the annual value of -$1.3 billion for FY2024, which is 1044453.78% down from last year.
  • Latest data reveals that United Therapeutics reported Cash from Financing Activities of -$956.0 million as of Q3 2025, which was down 139141.97% from -$198.6 million recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' Cash from Financing Activities peaked at $55.5 million during Q4 2022, and registered a low of -$1.1 billion during Q1 2024.
  • Over the past 5 years, United Therapeutics' median Cash from Financing Activities value was $7.0 million (recorded in 2022), while the average stood at -$126.0 million.
  • As far as peak fluctuations go, United Therapeutics' Cash from Financing Activities skyrocketed by 64000.0% in 2022, and later plummeted by 229753.09% in 2024.
  • Over the past 5 years, United Therapeutics' Cash from Financing Activities (Quarter) stood at $7.5 million in 2021, then skyrocketed by 640.0% to $55.5 million in 2022, then plummeted by 267.21% to -$92.8 million in 2023, then increased by 19.5% to -$74.7 million in 2024, then tumbled by 1179.79% to -$956.0 million in 2025.
  • Its Cash from Financing Activities stands at -$956.0 million for Q3 2025, versus -$198.6 million for Q2 2025 and -$93.8 million for Q1 2025.